Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
1. A method of treating a pathological condition in a mammal, the method comprising administering to mammal suffering from the pathological condition a composition comprising a therapeutically effective amount of a first component selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone and a therapeutically effective amount of a second component selected from the group consisting of rosemary, an extract derived from rosemary, a compound derived from rosemary, oleanolic acid and ursolic acid, wherein
a) the composition comprises from about 50 mg to about 7500 mg of the first component, and
b) said pathological condition is selected from the group consisting of inflammation, inflammation-associated disorders, arthritis, asthma, bronchitis, menstrual cramps, tendonitis, bursitis, skin-related conditions, gastrointestinal conditions, cancer, ophthalmic diseases, pulmonary inflammation, nervous system disorders, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, and central nervous damage; thereby treating said pathological condition.
2. The method of claim 1 , wherein the first component is derived from hops.
3. The method of claim 1 , wherein the second component is rosemary.
4. The method of claim 1 , wherein the second component is an extract derived from rosemary.
5. The method of claim 1 , wherein the second component is olcanolic acid or ursolic acid.
6. The method of claim 1 , wherein the composition further comprises a third component different from the second component, said third component is a triterpene species selected from the group consisting of oleanolic acid and ursolic acid.
7. The method of claim 1 , wherein the second component is a compound derived from rosemary that is selected from the group consisting of betulin, betulinic acid, carnosic acid, carnosol, carvacrol, chlorogenic acid, diosmetin, limonene, and luteolin.
8. The method of claim 1 , wherein the composition comprises about 0.5 to 5000 mg of the second component, wherein the second component is selected from the group consisting of rosemary, extract derived from rosemary, and a compound derived from rosemary.
9. The method of claim 8 , wherein the composition comprises about 5 to 2000 mg of the second component, wherein the second component is selected from the group consisting of rosemary, extract derived from rosemary, and a compound derived from rosemary.
10. The method of claim 6 , wherein the composition comprises about 0.035 to 3500 mg of the third component.
11. The method of claim 10 , wherein the composition comprises about 0.7 to 700 mg of the third component.
12. The method of claim 1 , wherein the composition comprises about 0.001 to 10 weight percent of the second component.
13. The method of claim 12 , wherein the composition comprises about 0. 1 to 1 weight percent of the second component.
14. The method of claim 1 , wherein a ratio of the first component to the second component is in the range of about 100:1 to about 1:100.
15. The method of claim 14 , wherein the ratio of the first component to the second component is in the range of about 50:1 to about 1:50.
16. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
17. The method of claim 1 wherein the composition is administered orally, topically, parenterally, or rectally.
18. The method of claim 1 , wherein the second component is a compound derived from rosemary that is selected from the group consisting of 1,8-cineole; 19-alpha-hydroxyursolic acid; 2-β-hydroxyoleanolic acid; 3-O-acetyloleanolic acid; 3-O-acetylursolic acid; 6-methoxy-luteolin-7-glucoside; 6-methoxyluteolin; 6-methoxyluteolin-7-glucoside; methoxyluteolin-7-methylether; 7-ethoxy-rosmanol; 7-methoxy-rosmanol; alpha-amyrin; alpha-humulene; alpha-hydroxyhydrocaffeic acid; alpha-pinene; alpha-terpinene; alpha-terpinenyl acetate; alpha-terpineol; alpha-thujone; apigenin; apigenin-7-glucoside; curcumene; benzyl-alcohol; β-amyrenone; β-amyrin; β-elemenev; β-pinene; betulin; betulinic acid; borneol; bornyl-acetate; caffeic acid; carnphene; camphor; carnosic acid; carnosol; carvacrol; carvone; caryophyllene; caryophyllene-oxide; chlorogenic acid; diosmetin; gamma-terpinene; hesperidin; isoborneol; linionene; luteolin; luteolin-3′-O-(3″-O-acetyl)-β-D-glucuronide; luteolin-3′-O-(4″-O-acetyl)-β-D-glucuronide; luteolin-3′-O-βD-glucuronide; luteolin-7-glucoside; methyl-eugenol; myrcene; neo-chlorogenic acid; nepetin; octanoic acid; oleanolic acid; p-cymene; piperitenone; rosmanol; rosmaric acid; rosmaricine; rosmaridiphenol; rosemarinic acid; rosmarinol; rosmariquinone; sahinene; sabinyl acetate; salicylates; salicylic acid-2-β-D-glucoside; squalene; terpinen-4-ol; terpinolene; thymol; trans-anethole; trans-carveol; ursolic acid; verbenone; and zingiberene.